In this review, the authors summarize the current state of knowledge of the biomolecular mechanisms of SGLT2 inhibition in cardiorenal protection (Figure 1) and the changes in biomarkers linked with diabetic kidney disease (DKD) and HF observed with the use of SGLT2-Is (Figure 2). This evidence concerns the gene SLC5A2 and diabetic kidney disease.